These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36516881)

  • 1. Outcome and molecular measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia patients with MEF2D fusions.
    Sun K; Chen WM; Wang X; Zhao XS; Li LD; Hao Y; Wang J; Xu N; Jiang Q; Jiang H; Xu LP; Wang Y; Zhang XH; Huang XJ; Qin YZ
    Hematol Oncol; 2023 Aug; 41(3):594-597. PubMed ID: 36516881
    [No Abstract]   [Full Text] [Related]  

  • 2.
    Sadras T; Müschen M
    Blood Cancer Discov; 2020 Jul; 1(1):18-20. PubMed ID: 34661138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEF2D-BCL9 B-Lymphoblastic Leukemia Blast Morphology Does Not Always Mimic Mature B-Cell Leukemia.
    Baek HJ; Choi YJ; Kim BR; Lee JH; Shin MG; Kook H
    J Pediatr Hematol Oncol; 2021 Apr; 43(3):112-113. PubMed ID: 33235148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and molecular characteristics of
    Ohki K; Kiyokawa N; Saito Y; Hirabayashi S; Nakabayashi K; Ichikawa H; Momozawa Y; Okamura K; Yoshimi A; Ogata-Kawata H; Sakamoto H; Kato M; Fukushima K; Hasegawa D; Fukushima H; Imai M; Kajiwara R; Koike T; Komori I; Matsui A; Mori M; Moriwaki K; Noguchi Y; Park MJ; Ueda T; Yamamoto S; Matsuda K; Yoshida T; Matsumoto K; Hata K; Kubo M; Matsubara Y; Takahashi H; Fukushima T; Hayashi Y; Koh K; Manabe A; Ohara A;
    Haematologica; 2019 Jan; 104(1):128-137. PubMed ID: 30171027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZNF384 fusion transcript levels for measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia.
    Shi ZY; Wang X; Chen WM; Li LD; Hao Y; Li JY; Sun K; Zhao XS; Jiang H; Jiang Q; Huang XJ; Qin YZ
    Hematol Oncol; 2024 Jan; 42(1):e3251. PubMed ID: 38287528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of MEF2D fusion in human B-cell precursor acute lymphoblastic leukemia cell lines.
    Akahane K; Yasuda T; Tsuzuki S; Hayakawa F; Kiyokawa N; Somazu S; Watanabe A; Kagami K; Abe M; Harama D; Goi K; Kawazu M; Kojima S; Imamura T; Goto H; Iwamoto S; Minegishi M; Abe M; Hojo H; Inaba T; Mano H; Sugita K; Inukai T
    Hematol Oncol; 2020 Oct; 38(4):614-617. PubMed ID: 32515032
    [No Abstract]   [Full Text] [Related]  

  • 7. MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents.
    Suzuki K; Okuno Y; Kawashima N; Muramatsu H; Okuno T; Wang X; Kataoka S; Sekiya Y; Hamada M; Murakami N; Kojima D; Narita K; Narita A; Sakaguchi H; Sakaguchi K; Yoshida N; Nishio N; Hama A; Takahashi Y; Kudo K; Kato K; Kojima S
    J Clin Oncol; 2016 Oct; 34(28):3451-9. PubMed ID: 27507882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEF2D-rearranged acute lymphoblastic leukemia resembles Burkitt lymphoma/leukemia.
    Sun J; Yu W; Zhang X
    Ann Hematol; 2020 Jan; 99(1):185-188. PubMed ID: 31781846
    [No Abstract]   [Full Text] [Related]  

  • 9. The Molecular and Biological Function of MEF2D in Leukemia.
    Zhang P; Lu R
    Adv Exp Med Biol; 2024; 1459():379-403. PubMed ID: 39017853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical characteristics and outcomes of childhood B-ALL with ZNF384 and MEF2D rearrangements].
    Hirabayashi S; Manabe A; Ohki K; Kiyokawa N
    Rinsho Ketsueki; 2023; 64(7):633-638. PubMed ID: 37544723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group.
    Ohki K; Butler ER; Kiyokawa N; Hirabayashi S; Bergmann AK; Möricke A; Boer JM; Cavé H; Cazzaniga G; Yeoh AEJ; Sanada M; Imamura T; Inaba H; Mullighan CG; Loh ML; Norén-Nyström U; Shih LY; Zaliova M; Pui CH; Haas OA; Harrison CJ; Moorman AV; Manabe A
    Leukemia; 2023 Jan; 37(1):212-216. PubMed ID: 36309560
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia.
    Desikan SP; Senapati J; Jabbour E; Abuasab T; Short N; Tang G; Wang S; Kebriaei P; Kadia T; Borthakur G; Ravandi F; Roberts K; Mullighan C; Konopleva M; Kantarjian H; Jain N
    Am J Hematol; 2023 Jun; 98(6):E142-E144. PubMed ID: 36877196
    [No Abstract]   [Full Text] [Related]  

  • 13. Characterization of a novel
    Van Outersterp I; Hormann FM; Hoogkamer AQ; Boeree A; Van den Broek SA; Den Boer ML; Boer JM
    Haematologica; 2023 Oct; 108(10):2859-2864. PubMed ID: 37051743
    [No Abstract]   [Full Text] [Related]  

  • 14. Two cases of very late relapsing ALL carrying the TEL:AML1 fusion gene.
    Chow CD; Dalla-Pozza L; Gottlieb DJ; Hertzberg MS
    Leukemia; 1999 Nov; 13(11):1893-4. PubMed ID: 10557067
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.
    Ribera J; Granada I; Morgades M; González T; Ciudad J; Such E; Calasanz MJ; Mercadal S; Coll R; González-Campos J; Tormo M; García-Cadenas I; Gil C; Cervera M; Barba P; Costa D; Ayala R; Bermúdez A; Orfao A; Ribera JM;
    Br J Haematol; 2022 Feb; 196(3):670-675. PubMed ID: 34549416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicentric standardization of minimal/measurable residual disease in B-cell precursor acute lymphoblastic leukaemia using next-generation flow cytometry in a low/middle-level income country.
    Ikoma-Colturato MRV; Bertolucci CM; Conti-Spilari JE; Oliveira E; Simioni AJ; Figueredo-Pontes LL; Furtado FM; Alegretti AP; Azambuja AP; Gevert F; Gomes BE; Avelar DMV; Soares ACCV; Ramos PM; Santos B; Cortez ML; Beltrame MP; Bacal NS; Wagner A; Lucena-Silva N; Sandes AF; Cunha F; Oliveira GHM; Costa ES; Yamamoto M
    Br J Haematol; 2023 Feb; 200(3):381-384. PubMed ID: 36222259
    [No Abstract]   [Full Text] [Related]  

  • 17. Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: a marker for the monitoring of minimal residual disease.
    Nakao M; Janssen JW; Erz D; Seriu T; Bartram CR
    Leukemia; 2000 Mar; 14(3):522-4. PubMed ID: 10720156
    [No Abstract]   [Full Text] [Related]  

  • 18. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.
    Gu Z; Churchman M; Roberts K; Li Y; Liu Y; Harvey RC; McCastlain K; Reshmi SC; Payne-Turner D; Iacobucci I; Shao Y; Chen IM; Valentine M; Pei D; Mungall KL; Mungall AJ; Ma Y; Moore R; Marra M; Stonerock E; Gastier-Foster JM; Devidas M; Dai Y; Wood B; Borowitz M; Larsen EE; Maloney K; Mattano LA; Angiolillo A; Salzer WL; Burke MJ; Gianni F; Spinelli O; Radich JP; Minden MD; Moorman AV; Patel B; Fielding AK; Rowe JM; Luger SM; Bhatia R; Aldoss I; Forman SJ; Kohlschmidt J; Mrózek K; Marcucci G; Bloomfield CD; Stock W; Kornblau S; Kantarjian HM; Konopleva M; Paietta E; Willman CL; Loh ML; Hunger SP; Mullighan CG
    Nat Commun; 2016 Nov; 7():13331. PubMed ID: 27824051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pathogenic role of MEF2D-SS18 fusion gene in B-cell acute lymphoblastic leukemia.
    Zhang M; Mao D; Zhang W
    Biochem Biophys Res Commun; 2018 Feb; 496(4):1331-1336. PubMed ID: 29408457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cell sorting followed by PCR-based clonality testing may assist in questionable diagnosis and monitoring of acute lymphoblastic leukemia.
    Semchenkova A; Zhogov V; Zakharova E; Mikhailova E; Illarionova O; Larin S; Novichkova G; Karachunskiy A; Maschan M; Popov A
    Int J Lab Hematol; 2023 Aug; 45(4):506-515. PubMed ID: 36871952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.